Home / Brands / Camber Pharmaceuticals
Camber Pharmaceuticals Recalls
5 recalls on record · March 27, 2019 to May 17, 2023 · Drugs
Recalls by year
19
22
23
Count of recall notices naming this brand, by the year the recall was announced. A quiet year is not proof of a safe year.
May 17, 2023DrugsFDA
Camber Pharmaceuticals Inc. recalls Atovaquone Oral Suspension USP, 750 mg/5 mL, Packaged in 210 mL bottle, Manufactured for: Camber Pharmaceuticals, Inc.,
Hazard: Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product.
December 21, 2022DrugsFDA
Camber Pharmaceuticals, Inc recalls Lacosamide Oral Solution, USP, CV, 10mg/mL, packaged in 200 mL bottle, Rx Only, Manufactured for: Camber Pharmaceuticals
Hazard: Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content
March 27, 2019DrugsFDA
Camber Pharmaceuticals Inc recalls Losartan Potassium Tablets USP, 100 mg, Rx only, a) 30 count (NDC 31722-702-30), b) 90 count (NDC 31722-702-30), c) 1000
Hazard: CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient
March 27, 2019DrugsFDA
Camber Pharmaceuticals Inc recalls Losartan Potassium Tablets USP, 50 mg, Rx only, a) 30 count (NDC 31722-701-30), b) 90 count (NDC 31722-701-90), c) 1000
Hazard: CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient
March 27, 2019DrugsFDA
Camber Pharmaceuticals Inc recalls Losartan Potassium Tablets USP, 25 mg, Rx only, a) 90 count (NDC 31722-700-90), b) 500 count (NDC 31722-700-05) and c) 1
Hazard: CGMP Deviations; trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) detected in the active pharmaceutical ingredient